Вы искали: med;med (Английский - Турецкий)

med
med

med ebb
muz firlat

j. med.
j. med.

kommunicera med oss
bize haber verin

j clin anal med.
j clin anal med.

program med value
program ortalama değeri

vad är fördelen med att köra jqs?
jqs kullanmanın avantajları nelerdir?

the island a continuous med root in the.
ardından güç ve açısını ayarlayın boş kovan at muz vur.

hur uppgraderas java runtime environment med hjälp av rpm?
java runtime environment yazılımını kaldırma

jogos de med ebb , jogos eb b , www.ebbonline.com.br , jogos de med ebb , ebb online
dave firlat , muz firlat , juegos muz , bananas , muz fırlat

pub-med central (www.pubmedcentral.nih.gov)
pub-med central (www.pubmedcentral.nih.gov)

turkey pledges support for sarkozy's "club med"
türkiye'den sarkozy'nin "club med" planına destek sözü

sprida java runtime environment (jre) över ett nätverk med hjälp av active directory
jre ile j2se platformu arasında ne fark vardır?

journal of the neurological sciences 307 (2011) 86–91 ve acta med iran.
journal of the neurological sciences 307 (2011) 86–91 ve acta med iran.

"lum, lunds universitet med"delar, 7:1999, 3 september 1999.
"lum, lunds universitet med"delar, 7:1999, 3 september 1999.

heading: low dose aspırın assocıated wıth a lower rısk of hepatocellular carcınoma sub heading: results of a study conducted among adults with chronic viral hepatitis İn sweden article text: worldwide, more than 500,000 cases of incident hepatocellular carcinoma are diagnosed each year, related primarily to chronic infection with hepatitis b or hepatitis c virus. although the incidences of hepatocellular carcinoma and liver-related death are reduced with hepatitis b viral suppression or hepatitis c eradication, they nonetheless persist in high-risk patients, including those with advanced fibrosis. thus, an urgent need remains to develop effective strategies to prevent hepatocellular carcinoma and reduce mortality from cirrhosis. three prior observational studies of this issue lacked detailed data regarding key determinants of hepatic outcomes, including underlying viral hepatitis, cirrhosis, and use of antiviral medication. moreover, information about aspirin-related bleeding events from an unselected population of patients with established chronic viral hepatitis would be valuable. the use of low-dose aspirin the study team examined the use of low-dose aspirin (≤160 mg) in relation to incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding among adults in sweden with confirmed chronic hepatitis b or hepatitis c infection. the investigators identified 50,275 adults who were diagnosed with chronic hepatitis b or hepatitis c from 2005 through 2015 and who did not have a history of aspirin use. in total 14,205 patients who were starting to take low-dose aspirin were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. with a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among non-users of aspirin (difference, −4.3 percentage points; 95% confidence interval [ci], −5.0 to −3.6; adjusted hazard ratio [hr], 0.69; 95% ci, 0.62 to 0.76). this inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hrs were 0.90 (95% ci, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% ci, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% ci, 0.42 to 0.70) for 5 or more years of use. ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, −6.9 percentage points [95% ci, −8.1 to −5.7]; adjusted hr 0.73 [95% ci, 0.67 to 0.81]). however, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and non-users of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% ci, −0.6 to 2.4). the authors concluded that in this registry study among adults with chronic viral hepatitis in sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. the findings were consistent regardless of sex, cause of hepatitis, or underlying compensated cirrhosis, which suggests that the benefits of aspirin may apply to a broad at-risk population. the results support the need for randomised clinical trials. referans: simon tg, duberg a-s, aleman s, et al. association of aspirin with hepatocellular carcinoma and liver-related mortality. n engl j med 2020; 382:1018-1028 doi: 10.1056/nejmoa1912035
başlık: düşük dozlu aspırın, hepatoselüler karsinoma alt riskiyle asosiye edildi alt başlık: İsveç'te kronik viral hepatitli yetişkinler arasında yapılan bir Çalışmanın sonuçları, makale: dünya çapında her yıl 500.000'den fazla hepatosellüler karsinom vakası teşhis edilmektedir. hepatit b veya hepatit c virüsü ile kronik enfeksiyon. hepatelüler karsinom ve karaciğerle ilişkili ölüm insidansı, hepatit b viral supresyonu veya